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  INTRODUCTION 
 
 Intravenous Regional Anaesthesia (IVRA) since its birth in the 
hands of August Bier in 1908 has become a valuable instrument in 
the repertoire of anaesthesia providers. This method enjoyed wide 
popularity for a long time. It was not long before simple and reliable 
techniques for brachial plexus developed, and the intravenous method 
declined in popularity. 
 
It was revived in 1963 by Holmes, who  used lignocaine 
because it appeared to give more reliable anaesthesia than procaine. 
With slight technical modifications IVRA, today is an ideal method 
of providing anaesthesia for minor surgical procedures to the 
extremities performed on an ambulatory basis.  It has the advantages 
of speed of onset, rapid recovery, reliability of blockade  & cost 
effectiveness. 
 
 Adjuvants to local anaesthetics have greatly expanded the 
potential applications of regional anaesthesia by providing faster 
onset time, inhibition of tourniquet pain, prolonged post-operative 
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anaesthesia and improved peri-operative analgesia apart from 
decreasing risk of local anaesthetic toxicity. 
 
 In this regard, DEXAMETHASONE – a parenterally 
administered steroidal drug by decreasing tissue prostaglandin (PG) 
and other inflammatory mediator synthesis, decreases peri-operative 
pain in combination with LA.   
 
 Cumulative effects of these agents result in greater patient 
satisfaction, rapid hospital discharge , cost effectiveness and minimal 
risks. 
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AIM OF THE STUDY 
To prove the effectiveness of  DEXAMETHASONE  as an 
adjuvant in Intravenous Regional Anaesthesia and to know its 
effectiveness  in  relieving tourniquet pain &  providing post 
operative analgesia in  IVRA. 
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INTRAVENOUS REGIONAL ANAESTHESIA 
 
Intravenous regional anaesthesia (IVRA) was first described by 
August Bier in 1908. He observed that when local anaesthetic was 
injected intravenously between two tourniquets on a limb, a rapid 
onset of anaesthesia occurred in the area between the tourniquets and 
a slower onset occurred beyond the distal tourniquet. The technique 
did not become popular until the 1960s when it was reintroduced by 
Holmes. Today, the technique is slightly modified, using either a 
single or a double tourniquet at one site and injecting local 
anaesthetic as distal as possible to the cuff. The double tourniquet is 
used to increase safety and to reduce tourniquet pain in the awake 
patient, but there is a possibility of accidental deflation of the wrong 
cuff, which may lead to toxic systemic levels of local anaesthetic. 
IVRA is technically simple and does not require specific 
anatomical knowledge. Success rate is 96–100% with a low incidence 
of side-effects. It is a reliable, simple and safe method of providing 
anaesthesia for minor surgical procedures to the extremities if it is 
administered by experienced clinicians. 
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ADVANTAGES AND DISADVANTAGES OF INTRAVENOUS 
REGIONAL ANAESTHESIA 
Advantages : 
 Speed of onset and rapid recovery 
 Reliability (in the absence of local infection and with adequate  
  equipment) 
 Muscle relaxation 
 Technical simplicity 
Disadvantages and Complications 
• Poor postoperative analgesia 
• Limited time of surgical anaesthesia ( < 90 minutes) 
• The potential of systemic local anaesthetic toxicity 
• Nerve damage secondary to direct compression by the  
tourniquet. 
• Compartment syndrome and loss of limb (very rare) 
Mechanisms of action:  
Local anaesthetic diffuses into the small veins surrounding the 
nerves and then into the vasa nervorum and capillary plexus of the 
nerves, leading to a core to mantle (centrifugal) conduction block in 
the nerves involved. Local anaesthetic then diffuses into the small 
nerves in the skin, blocking their conduction. The tourniquet 
 12
produces ischaemia, which contributes to the analgesic action of the 
local anaesthetic by blocking nerve conduction and motor endplate 
function. 20 minutes after tourniquet application alone there will be 
analgesia to pinprick without the injection of any local anaesthetic. 
However, the speed of onset and the density of anaesthesia are 
greater with injection of local anaesthetic. 
Indications: 
IVRA is used for surgical interventions on the hand, forearm or 
elbow that will not exceed 1 hour. These include manipulation of 
forearm fractures, excision of wrist ganglia and palmar fasciotomy. 
IVRA is particularly useful for tendon grafting because it enables the 
surgeon to observe movement and tension of the grafted tendon (after 
deflating the tourniquet) before closing the wound (continued 
anaesthesia with a wrist block). IVRA can also be used for surgery on 
the foot, ankle or lower leg, for example for removing plates, screws 
or foreign bodies. Surgery on the elbow or knee is poorly tolerated 
using IVRA. 
Contraindications are mainly related to tourniquet use. Absolute 
contraindications include sickle cell disease, Raynaud’s disease or 
scleroderma, allergy to local anaesthetics and patient refusal. Relative 
contraindications include severe hypertensive or peripheral vascular 
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disease, local infection, and skeletal muscle disorders or Paget’s 
disease (local anaesthetic may spread to the systemic circulation via 
venous channels in bone). 
Procedure 
Before the procedure the patient should be: 
 starved for 6 hours  
 monitored closely (standard monitoring applied)  
 placed on a tipping trolley  
 adequately informed about the procedure and should have  
 consented to it. 
The equipment required for IVRA includes: 
 pneumatic tourniquet (checked for leaks before the  
    procedure) and a pressure gauge  
 Esmarch bandage or Rhys-Davis exsanguinator  
 local anaesthetic solution  
 resuscitation equipment and drugs. 
IVRA of the arm:  
A 22 G cannula is placed intravenously as distal as possible in 
the arm to be anaesthetized. Venous access is established in the 
opposite arm to allow administration of fluids or drugs if necessary. 
The double tourniquet (two tourniquets each 6 cm wide) or a single 
one (14 cm wide) is applied on the arm with generous layers of 
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padding, ensuring that no wrinkles are formed and the tourniquet 
edges do not touch the skin. The arm is exsanguinated either by using 
the Esmarch bandage or a Rhys-Davis exsanguinator. If this is 
impossible, exsanguination can be achieved by elevating the arm for 
2–3 minutes while compressing the axillary artery. The distal 
tourniquet is inflated to at least 100 mmHg higher than the patient’s 
systolic blood pressure (250–300 mmHg). The proximal tourniquet is 
inflated to the same pressure. After ensuring inflation, the distal cuff 
is deflated. 
Before injecting local anaesthetic it must be confirmed that no 
radial pulse is palpable. The local anaesthetic is then injected slowly. 
A standard volume for injection into the upper limb is 40 ml, which 
can be increased to 50 ml in a fit, large adult. If the injection is too 
rapid, the venous pressure may exceed the tourniquet pressure and 
the local anaesthetic solution may escape into the systemic 
circulation. Surgical anaesthesia is usually achieved within 15 
minutes. The distal tourniquet, which overlies part of the 
anaesthetized arm, can then be inflated and the proximal one deflated 
to relieve tourniquet pain. 
The cuff should not be deflated until 20 minutes after local 
anaesthetic injection because systemic toxic doses of local 
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anaesthetic may occur. After 20 minutes, 30% of the injected drug is 
fixed within the tissues and is unavailable for immediate release into 
the systemic circulation. Cuff deflation should be performed in cycles 
with deflation/inflation times of less than 10 seconds until the patient 
no longer exhibits signs of systemic toxicity (e.g. tingling of the lips, 
tinnitus, drowsiness). Severe signs of systemic toxicity include 
bradycardia, hypotension, ECG abnormalities, seizures and loss of 
consciousness. Maximum blood levels of local anaesthesia occur 
within 10 minutes of cuff deflation. Therefore, the patient should be 
monitored closely for 30 minutes following tourniquet release. With 
lignocaine, 2.5–3 mg/kg, and cuff deflation after 10 minutes, blood 
levels have been reported to be less than 2 micrograms/ml. 
If severe CNS intoxication occurs, appropriate resuscitation 
guidelines should be followed. Emergency drugs must be readily 
available and 100% oxygen should be administered. 
IVRA of the leg:  
The basic technique is the same as for the arm but the dose and 
volume of local anaesthetic has to be doubled for IVRA of the leg, 
which is associated with an increased potential for local anaesthetic 
toxicity. The tourniquet pressure must be higher in the leg (350–400 
mmHg), to occlude blood flow in the femoral artery. This may 
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increase the occurrence of tourniquet pain. Tourniquets may be 
applied to the thigh (two tourniquets about 9 cm wide) or one at the 
calf (below the head of the fibula) and one at the thigh. The latter is 
for safety in case of distal cuff failure and is not usually inflated. 
Choice of drugs 
Many local anaesthetic drugs, with or without additives, have 
been used for IVRA, but 0.5% prilocaine, 3–6 mg/kg, is the drug of 
choice because it has less systemic toxicity and is partially taken up 
in the lungs before reaching the systemic circulation. The usual dose 
is 40 ml (200 mg) without epinephrine. However, the manufacturers 
have ceased production of 0.5% prilocaine. 1% prilocaine remains 
available and is licensed for IVRA, though its stability is not 
guaranteed if diluted.  If prilocaine is unavailable  0.5% lignocaine, 3 
mg/kg, is used. If IVRA is applied to the leg a larger volume must be 
injected (up to 100 ml). Prilocaine can be used undiluted (maximum 
recommended dose is 400 mg in adults) but lignocaine is commonly 
diluted to lower concentrations (e.g. 0.2–0.25%). 
Prilocaine can cause methaemoglobinaemia but unless doses in 
excess of 600 mg are used it is clinically insignificant in most 
patients. Although one has to be aware that in patients with anaemia 
or cardiac conditions even small amounts of methaemoglobin can 
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significantly impair the oxygen-carrying capacity of their red blood 
cells. Intravenous regional anaesthesia with prilocaine in these 
patients should be considered carefully for its benefits. 
Other local anaesthetic agents have been used but do not 
provide superior analgesia or more rapid onset of block. Severe toxic 
reactions and death have been observed with bupivacaine and its use 
is contraindicated. In one study, 0.2% ropivacaine was 
intraoperatively as effective as 0.5% prilocaine but postoperative 
analgesia was prolonged;  
Additives to local anaesthetics have not been consistently 
shown to have an effect during IVRA but may increase the length of 
postoperative analgesia, probably because of a systemic effect 
following tourniquet release. The reported enhancement of IVRA 
with pethidine, 1 mg/kg, may reflect intrinsic local anaesthetic 
activity of the drug. 
Experiments with the addition of muscle relaxants produced 
marked muscle relaxation but did not augment analgesia. 
        Ketamine alone appears to provide good sensory analgesia but 
some patients lost consciousness and exhibited the typical features of 
ketamine anaesthesia after tourniquet release. 
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Many other drugs have been studied, but only the addition of 
clonidine, 150 micrograms, an α 2-agonist, or the non-steroidal anti-
inflammatory drugs ketorolac, 20 mg, or tenoxicam, 20 mg, to the 
local anaesthetic solution appeared to be effective in prolonging 
postoperative analgesia and relieving tourniquet pain. Guanethidine 
and calcium-channel blockers have been evaluated in the context of 
chronic pain management only . 
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                                                  TOURNIQUET 
Intravenous regional anaesthesia is a method of producing 
analgesia of the distal part of a limb by intravenous injection, while 
circulation to the limb is occluded. 
 Occlusion of the limb was done previously by winding an 
Esmarch bandage proximally up the arm. Now occlusion of the limb 
was achieved by pneumatic tourniquet. Unfortunately, the tourniquet 
is not physiologic and is associated with number of disadvantages. 
SITE OF APPLICAION: 
 The upper arm and thigh have sufficient muscle built  to 
distribute the cuff pressure evenly and are recommended sites. 
CUFF WIDTH: 
 The American Heart Association concluded that if a 
sphygmomanometer cuff has a width of 20% greater than the 
diameter of the upper arm or 40% of the circumference of the thigh 
(to a maximum of 20cm), then the pressure in the underlying central 
artery will be equal to that in the cuff.  Modern silicone cuffs tend to 
be smaller than this, measuring 90mm width ( bladder 70mm) for the 
arm and 105mm (bladder 75mm) for the leg. 
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              The tissues immediately underlying the cuff should be 
protected with cotton wool. This is not necessary with correctly 
applied modern silicone cuff.  
 PRESSURE: 
 It was based on the unsedated patient’s blood pressure 
measured in the ward with the adult sized cuff. The recommended 
cuff pressure for the upper limb is systolic BP plus 100mmHg and for 
lower limb twice systolic BP. This higher pressure is needed because 
there is often not enough room above the operating site for full sized 
cuff 
TOURNIQUET TIME: 
 The recommended time for upper limb is 90minutes. Two 
hours should be regarded as a maximum but this will not be safe for 
all patients. Notify the surgeon about tourniquet time every half an 
hour. 
CONTRAINDICATIONS: 
¾ Sickle cell disease 
¾ Raynaud’s disease and other peripheral vascular disease 
¾ Tumour or severe infection at the site of application 
¾ Severe left ventricular failure 
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¾ Deep venous thrombosis- Massive total pulmonary embolism 
has been reported. 
 
PHYSIOLOGIC CHANGES CAUSED BY LIMB 
TOURNIQUETS: 
NEUROLOGIC EFFECTS: 
1. Abolition of somatosensory evoked potentials and nerve 
conduction occurs with in 30minutes 
2. Application for more than 60minutes causes tourniquet pain 
and hypertension 
3. Application for more than 2hours may result in postoperative 
neuropraxia 
4. Evidence of nerve injury may occur at a skin level underlying 
the edge of the tourniquet 
MUSCLE CHANGES: 
¾ Cellular hypoxia develops within 8minutes 
¾ Cellular creatine level declines 
¾ Progressive cellular acidosis occurs 
¾ Endothelial capillary leak develops after 2hours 
¾ Limb becomes progressively colder 
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SYSTEMIC EFFECTS OF TOURNIQUET INFLATION: 
 Arterial and pulmonary artery pressures become elevated, 
although this effect is usually slight to moderate if only one limb is 
occluded. 
SYSTEMIC EFFECTS OF TOURNIQUET RELEASE: 
¾ Transient fall in core temperature 
¾ Transient metabolic acidosis 
¾ Transient fall in central venous oxygen tension 
¾ Rapid release of acid metabolites into central circulation 
¾ Transient fall in pulmonary and systemic arterial pressures. 
¾ Transient increase in end – tidal carbondioxide 
¾ Increased oxygen consumption 
TOURNIQUET PAIN: 
 Patients receiving spinal anaesthesia may develop a poorly 
defined aching or burning sensation in the distal extremity about one 
hour after tourniquet inflation. Although the mechanism and neural 
pathways for this severe aching and burning sensation defy precise 
explanation, unmyelinated, slow –conduction C fibres, which are 
relatively resistant to local anaesthetic blockade, probably play a 
critical role. Even during general anaesthesia, tourniquet pain can be 
revealed by a gradually increasing mean arterial blood pressure. The 
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tourniquet pain and its accompanying hypertension influenced by 
many factors including anaesthetic technique (IVRA > Epidural> 
Spinal> GA), intensity and level of block, choice of local anaesthetic 
(hyperbaric spinal with tetracaine > isobaric bupivacaine), and 
supplementation of the block with opioids. Cuff deflation invariably 
and immediately relieves the sensation of tourniquet pain and its 
hypertension. Systemic opioids have questionable value in relieving 
tourniquet pain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24
PHARMACOLOGY  OF LIGNOCAINE 
Lignocaine is a synthetic amide-linked anaesthetic of 
intermediate potency and duration.  In 1943 Lofgren synthesized 
Lignocaine in Sweden. First used by Gordh in 1948. 
Lignocaine is the standard to which all other local anaesthetics 
are compared.  It is currently the most widely used local anaesthetic.  
In addition, it is a popular antiarrythmic.  It can be given by almost 
any route. 
Mechanism of action : 
 Lignocaine prevents transmission of nerve impulses by 
inhibiting passage of sodium ions through ion-selective sodium 
channels in the nerve membranes.  This slows the rate of 
depolarization such that the threshold potential is not reached and 
thus action potential is not propagated.  But resting membrane 
potential is not altered.  Lignocaine binds to the inner portion 
receptor (i.e Sodium channel) after entering the cell membrane. 
Physiochemical properties : 
 Molecular weight 234 
 Weak base with a pka 7.6 – 7.8 
 Very stable, not decomposed by boiling, acids or alkalies 
 It is less lipid soluble than that of Bupivacaine 
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Pharmacokinetics : 
Absorption : 
 It is absorbed from the site of application or injection into the 
blood stream.  Rate of absorption depends on the blood flow to the 
area and use of epinephrine. 
Metabolism : 
 Metabolised in liver by oxidative dealkylation to 
monoethylglycine xylidide followed by hydrolysis of this metabolite 
to xylidide.  Metabolism is dependant on hepatic blood flow. 
 Monoethylglycine xylidide has 80% activity of the parent drug. 
 Xylidide has 10% activity of the parent drug. 
 75% of xylidide is excreted in the urine as 4 – hydroxyl – 2,6 –
dimethylaniline. 
Onset of action : 
 Rapid onset of action 
 Topical anaesthesia  5-10 mins 
 Conduction anaesthesia 
   For small nerves  5-10 mins 
   For large nerves  10-15 mins 
 Intravenous administration 1-2 mins 
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Protein binding : 
 It is 70% bound to α 1 acid glycoprotein. 
Volume of distribution : 
 91 litres 
Distribution : 
 Lignocaine has a triphasic distribution 
Rapid distribution phase (α)  : 
 In this phase, the drug is distributed to highly vascular regions.  
t ½ α is 1 min. 
Slow disappearance phase (β) : 
 The drug is distributed to slowly equilibrating tissues. 
 t ½ β is 9.6 min. 
Slow transformation and excretion phase ( δ )  : 
 t ½ is δ is 1.6 hrs 
 Clearance is 0.95 litres per minute 
Availability : 
a) 5% heavy 2 ml ampoules which contain 50 mg of lignocaine / 
ml with 75 mg – 100 mg of dextrose. 
b) 2% lignocaine (xylocard) without preservative – 50 ml vial for 
intravenous use. 
c) 2% lignocaine – plain – 30 ml vial –contains methyl and 
propyl paraben as preservative. 
d) 4% lignocaine with 1 in 200000 Adrenaline – 30 ml vial. 
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e) 4% lignocaine viscous 
f) 4% lignocaine aqueous solution 
g) 10% lignocaine spray 
h) 2% lignocaine Jelly 
i) 2% lignocaine ointment  
j) 5% lignocaine ointment 
Pharmacodynamics : 
Local actions : 
 Causes nerve blockade with loss of pain and temperature 
sensation, touch, motor power and vasomotor tone in the region 
supplied by the nerves blocked. 
Systemic actions : 
 Result of systemic absorption from the site of administration or 
intravenous administration 
Cardiovascular system : 
 It has a stabilizing effect on the cell membranes of cardiac 
tissue. 
 Lignocaine depresses myocardial automaticity by antagonizing 
the spontaneous phase IV depolarization and reduces the duration of 
effective refractory period. 
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 Myocardial contractility and conduction velocity are depressed 
at higher concentrations. 
 These effects result from direct cardiac muscle membrane 
changes (ie.) cardiac sodium channel blockade. 
 It stabilizes the membrane of damaged and excitable cells, 
tending to suppress ectopic foci. 
Respiratory system : 
Lignocaine depresses hypoxic drive (the ventilatory response 
to low PaO2). 
 Apnea can result from phrenic and intercostal nerve paralysis 
or depression of the medullary respiratory center following direct 
exposure to the local anaesthetic agents. 
 Relaxes bronchial smooth muscle. 
 Intravenous lignocaine may be effective in blocking the reflex 
bronchoconstriction associated with intubation. 
Vascular smooth muscle : 
 Produces vasodilatation 
 
Central nervous system : 
 Produces a sequence of stimulation followed by depression. 
Produces sedation on intravenous administration. 
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 Intravenous administration decreases cerebral blood flow and 
attenuates the rise in intracranial pressure that accompanies 
intubation. 
 Infusion of lignocaine is capable of reducing the MAC of 
volatile anaesthetics by 40%. 
Musculoskeletal : 
 Lignocaine is myotoxic leading to lytic degeneration, edema 
and necrosis. 
Haematological : 
 It decreases coagulation and enhances fibrinolysis 
Indications : 
1. For infiltration block, peripheral nerve blocks, epidural, spinal 
        and topical anaesthesia & intravenous regional anaesthesia. 
2. Antiarrythmic : 
Lignocaine is a class IB antiarrythmic. 
Ventricular tachyarrythmias 
Arrythmias following acute MI during cardiac surgery 
In digitalis toxicity – because it does not worsen AV – block. 
3. Prevention or treatment of increases in intracranial pressure 
 during intubation. 
-     antitussive effect may be the reason. 
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4. Reflex induced bronchospasm is also attenuated by iv 
administration of lignocaine 
5. Suppresses noxious reflexes such as coughing & sympathetic 
stimulations associated with endotracheal suctioning and intubation. 
6. Used as an antiepileptic agent intravenously 
7. Used intravenously as an analgesic for certain chronic pain states 
8. Used as a supplement to general anesthesia. 
Contraindications  
1. Hypersensitivity 
     2. Should not be used with vasoconstrictors in digits of hands, feet        
and penis 
 Stokes Adams syndrome, severe degree of heart block 
Doses : 
Maximum recommended dose : 
 a) Plain  - 3 mg / kg 
 b) with adrenaline- 7 mg / kg 
 c) for reflex suppression  -  1.5 mg / kg  iv. 
Drug interactions : 
β  Blockers : 
 Coadministration of betablockers- increases serum levels of 
lignocaine and its toxicity by decreasing lignocaine’s metabolism. 
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Anticonvulsant agents : 
 Increases lignocaine’s metabolism 
Non depolarizing muscle relaxant 
 Blockade is potentiated by lignocaine 
Opioids and  α 2 adrenergic agonists : 
 Potentiate lignocaine’s pain relief 
Antiarrythmic agents 
 Potentiate the cardiac effects of lignocaine 
Toxicity  : 
 Mostly due to systemic absorption of locally administered 
lignocaine or due to accidental intravenous administration of large 
doses of lignocaine. 
 The central nervous system is mostly vulnerable. 
Blood levels and symptoms : 
 4 µg / ml  :  Light headedness, tinnitus, circumoral and tongue 
numbness   ( anticonvulsant and antiarrhythmic activity) 
 6 µg / ml :   visual disturbances 
 8 µg / ml  :   muscular twitching 
 10 µg / ml :   convulsions 
 12 µg / ml  :  Unconsciousness 
 15 µg / ml  :  Coma 
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 20 µg / ml  :  respiratory arrest 
 26 µg / ml   : cardiovascular collapse 
Treatment of toxicity : 
 Continuous monitoring of CVS and RS status helps to identify 
the toxicity earlier. 
 If convulsions occur barbiturates or benzodiazepines can be 
given. 
 Succinylcholine  1 mg / kg to paralyse the patient and aids in 
controlling the seizures. 
 Cardiac toxicity like fibrillation can be treated by defibrillation 
 Ventilatory support – 100 % oxygenation, intubation etc., 
 Maintain B.P. by rapid infusion of I.V. fluids, use of 
vasopressors and put the patient in Trendelenberg’s position. 
 Maintain fluid and electrolyte balance. 
Adverse effects : 
1. Allergic and hypersensitivity reactions 
  Due to the preservative used – methyparaben 
2. CVS :  Bradycardia, hypotension 
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              PHARMACOLOGY OF DEXAMETHASONE 
 
 
              Dexamethasone Sodium Phosphate Injection,  is a synthetic 
 adrenocortical steroid anti-inflammatory drug. It has got the 
following  structure. 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
Dexamethasone Sodium Phosphate Injection, has a molecular 
 weight of 516.41 and the chemical name 9-fluoro-11β,17,21-
trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 21-(dihydrogen 
phosphate) disodium salt. 
          Dexamethasone Sodium Phosphate Injection,  4 mg/mL is a 
sterile solution for intravenous, intramuscular, intra-articular, 
intralesional and soft tissue administration. 
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Mechanism of action: 
The primary anti-inflammatory action is through inhibition of 
prostaglandin and leukotriene synthesis, increased antioxidant 
activity, and cell membrane stabilisation. It depresses formation, 
release, and activity of endogenous mediators of inflammation, 
including prostaglandins, kinins, histamine, liposomal enzymes, and 
complement expression. Also modifies the body's immune response. 
 Pharmacodynamics: 
The half lives after intravenous and intramuscular 
administration were 5.4 hours and 7.4 hours, respectively. It is 
metabolized in the liver by the enzyme cytochrome P-450 
AVAILABLE ROUTES: 
      Intravenous,intramuscular and intraarticular preparations are 
 available. 
DOSAGE: 
Dexamethasone- all other inflammatory conditions: 
Initial dose PO 0.75 to 9 mg/day. 
Indications 
Dexamethasone is indicated for short-term management of 
pain mainly, postoperative pain and musculoskeletal pain.  It can be 
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used with opioid analgesic in general anaesthesia and as adjuvant for 
local anaesthetic  in IVRA and apart from these  they can be used in 
   a. Allergic states 
   b. dermatologic diseases. 
   c. endocrine disorders. 
   d. gastrointestinal diseases-ulcerative colitis. 
   e. hemotological diseases 
   f. neoplastic diseases. 
Contraindications: 
    Depending on the indication and the general condition, peptic  
ulcers, osteoporosis, psychoses, infectious diseases, fungal infections 
diabetes and hypertension can be considered contraindications. 
ADVERSE EFFECTS: 
Some of the adverse effects seen with respect to individual 
systems. 
Adverse Reactions 
Fluid and electrolyte disturbances: 
 Sodium retention 
  Fluid retention 
  Congestive heart failure in susceptible patients 
  
Potassium loss 
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Hypokalemic alkalosis 
  
Hypertension 
 
Musculoskeletal: 
  
Muscle weakness 
  
Steroid myopathy 
  
Loss of muscle mass 
  
Osteoporosis 
  
Vertebral compression fractures 
  
Aseptic necrosis of femoral and humeral heads 
  
Pathologic fracture of long bones 
  
Tendon rupture 
 
Gastrointestinal: 
  
Peptic ulcer with possible subsequent perforation and 
hemorrhage Perforation of the small and large bowel, particularly in 
patients with inflammatory bowel disease 
 Pancreatitis 
 Abdominal distention 
  
Ulcerative esophagitis 
 
Dermatologic: 
  
Impaired wound healing 
  
Thin fragile skin 
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Petechiae and ecchymoses 
  
Erythema 
  
Increased sweating 
  
May suppress reactions to skin tests 
  
Burning or tingling, especially in the perineal area (after I.V. 
injection) 
 Other cutaneous reactions, such as allergic dermatitis, urticaria, 
          angioneurotic edema 
Neurologic: 
  convulsions 
  
Increased intracranial pressure with papilloedema 
(pseudotumor cerebri) usually after treatment 
  
Vertigo 
  
Headache 
  
Psychic disturbances 
 
Endocrine: 
  
Menstrual irregularities 
  
Development of cushingoid state 
  
Suppression of growth in children 
  
Secondary adrenocortical and pituitary unresponsiveness, 
particularly in times of stress, as in trauma, surgery, or illness 
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Decreased carbohydrate tolerance 
  
Manifestations of latent diabetes mellitus 
  
Increased requirements for insulin or oral hypoglycemic agents 
in diabetics 
  
Hirsutism 
 
Ophthalmic: 
  
Posterior subcapsular cataracts 
  
Increased intraocular pressure 
  
Glaucoma 
   
Exophthalmos 
 
Metabolic: 
  Negative nitrogen balance due to protein catabolism 
Cardiovascular:  
Myocardial rupture following recent myocardial infarction  
Other:  
Anaphylactoid or hypersensitivity reactions 
  Thromboembolism  
Weight gain  
Increased appetite  
Nausea  
Malaise  
Hiccups 
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Rare instances of blindness associated with intralesional 
therapy around the face and head 
  
Hyperpigmentation or hypopigmentation 
  
Subcutaneous and cutaneous atrophy 
  
Sterile abscess 
  
Postinjection flare (following intra-articular use) 
  
Charcot-like arthropathy 
 
Precautions 
 
Renal Function 
Use cautiously; monitor renal function. 
Adrenal suppression 
Prolonged therapy may lead to hypothalamic-pituitary-adrenal  
suppression. 
Fluid and electrolyte balance 
Can cause elevated BP, salt and water retention, and increased  
potassium and calcium excretion. Dietary salt restriction and 
potassium supplementation may be needed. 
GI 
Because of increased risk of perforation, use with caution in patients  
with diverticulitis, fresh intestinal anastomosis, latent peptic ulcers, 
or nonspecific ulcerative colitis. 
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Infections 
May mask signs of infection. May decrease host-defense 
mechanisms to prevent dissemination of infection. 
Stress 
Increased dosage of rapidly acting corticosteroid may be 
needed before, during, and after stressful situations. 
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1. ANAESTHESIA AND ANALGESIA 2006; 102:605-608   
Dexamethasone Improves the Quality of Intravenous  Regional 
Anaesthesia and Analgesia. A Randomized,                    
Controlled Clinical Study :   
Zekiye Bigat, Neval Boztug, Necmiye Hadimioglu, Niha 
conducted a randomized controlled study and in this 75 patients were 
divided into three groups and received plain lignocaine-(group L,) 
(IVRA), lignocaine with dexamethasone in IVRA (group LD)  and 
lignocaine with  dexamethasone intravenously in the opposite arm. 
LDc The volume was  40 ml of 0.5 % lignocaine in each of the 
groups. Patients in group LD reported significantly lower pain scores 
and  required less acetaminophen in the first 24 hrs after surgery. In 
Conclusion, the addition of 8 mg dexamethasone to lignocaine for 
IVRA in patients undergoing  hand surgery improves postoperative  
analgesia during the postop period. 
2. Anesthesia and Analgesia 1997;84:376–8.“Epidural 
dexamethasone reduces the incidence of backache after lumbar 
epidural anaesthesia.” YL.Yang,,,  PP.Tang. SC,Tsai… CH Yang. 
In this study 1000 patients were divided into 2 groups of     
Epidural lignocaine 2 %with dexamethasone  and epidural   
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lignocaine 2 %. It was found that the patients receiving epidural     
lignocaine 2%. and  dexamethasone had significantly lower pain 
scores     
3.   Anesthesiology 2002;96:1331–5                                         
“The dose response and effects of Dexamethasone on bupivacaine 
microcapsules for intercostal blockade (T9–T11) in healthy 
volunteers.˝Dan.J.Kopacz, Peter.G.Lacouter.Danlin Wu,Partha 
Nandy. In this study healthy volunteers were given Bupivacaine with 
Dexamethasone incorporated biodegradable microcapsules into the 
intercostal nerves. It was compared with plain Bupivacaine. The 
onset times, duration and efficacy of dexamethasone incorporated 
blocks were much higher when compared to the plain group. 
4.ANAESTHESIA AND ANALGESIA 2002: 105;  481-486 
 
 “The prolonged post operative analgesia when Dexamethasone is 
added to a  NSAID in Breast surgeries.” Hval Kjetil,  Thagaard K. 
Sem, Schlichting Ellen, and Raeder Johan, In this study 
Dexamethasone was found to prolong postoperative analgesia when 
added to an NSAID –Rofecoxib in a multimodal regimen. 
.  5. ANAESTHESIA AND ANALGESIA: NOVEMBER 2002 
.Intravenous Regional Anaesthesia using prilocaine and neostigmine: 
A. Turan, B. Karamanlyog M, D. Memis, G. Kaya and Z. 
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PaukcyDepartment of Anaesthesiology and Reanimation, Trakya 
University, Turkey. In this study, thirty patients undergoing hand 
surgery were randomly assigned to two groups to receive IVRA.  
They have used 0.5 mg of neostigmine as an additive.  They found 
shortened sensory and motor block onset times, improved quality of 
anaesthesia and prolonged sensory and motor block recovery times, 
and prolonged time to first analgesic requirement in the neostigmine 
groups. 
 
.  6. CANADIAN JOURNAL OF ANAESTHESIA SEPTEMBER 
2006 : “Epidural dexamethasone reduces postoperative pain and 
analgesic requirements״ In this study 94 patients undergoing 
laparoscopic cholecystectomy were administered epidural blockade 
with group 1 given intravenously  Dexamethasone and epidural 
Bupivacaine 0.25 % .Group 2 was given epidural Dexamethasone 
and Bupivacaine 0.25%. and group 3 was given epidural 
dexamethasone alone. It was concluded that groups receiving 
epidural dexamethasone had prolonged post operative analgesia  and 
decreased opioid requirements when  compared to the intravenous 
dexamethasone groups. 
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7. Anesthesia and Analgesia  2002;95:457-460 
An evaluation of the analgesic efficacy of intravenous regional 
anaesthesia with lidocaine and ketorolac using a forearm versus 
upper arm tourniquet.   Scott s. Reuben, MD., Robert B. Steinberg, 
MD, PhD, Holly Maciolek, RN and Poornachandran Manikantan 
MD, Department of Anaesthesiology, Tuffs University School of 
Medicine, Massachusetts. In this study, they assessed the analgesic 
efficacy of administering IVRA by administrating lidocaine and 
ketorolac with either a forearm or upper arm tourniquet for outpatient 
hand surgery.  They concluded that forearm tourniquet intravenous 
regional anaesthesia with 0.5% lidocaine and ketorolac provides  both 
a longer duration of sensory block and prolonged postoperative 
analgesia compared with upper arm IVRA. found in neostigmine 
group. 
8. ANAESTHESIA AND ANALGESIA 2006 102: 263-267 
 Dexamethasone Added to Lignocaine Prolongs Axillary Brachial 
Plexus Blockade  Sixty patients scheduled for elective hand and 
forearm surgery had axillary brachial plexus block were randomly 
allocated to receive either 34 mL lidocaine 1.5% with 2 mL of 
isotonic saline  chloride (control group,) or 34 mL lidocaine 1.5% 
with 2 mL of Dexamethasone (8 mg) (dexamethasone group), Neither  
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epinephrine nor bicarbonate was added to the treatment mixture. The 
duration of surgery and the onset times of sensory and motor block 
were similar in the two groups. The duration of sensory (242 ± 76 
versus 98 ± 33 min) and  motor (310 ± 81 versus 130 ± 31 min) 
blockade  were significantly longer in the dexamethasone than in the 
control  group (P < 0.01). It was concluded that the addition of   
dexamethasone to lidocaine 1.5% solution in axillary brachial  plexus 
block prolongs the duration of sensory and motor blockade.  
9.  ANESTHESIA AND ANALGESIA 2006; 88:430-44  
   0.5 % versus 1.0%  2 – chlorprocaine for Intravenous Regional 
Anaesthesia : A prospective randomized, Double – Blind Trial. 
Stephan C. Marsch, MD, D Phil, Mathias Sluga, MD, Wolfgang 
studier, MD, Jonas Barandun, MD, Domenic Scharplatz, MD and 
wolf gang Ummentioter MD, From the Departments of Anaesthesia 
and surgery, Switzerland. In this randomized prospective double – 
blind study they tested the hypothesis that compared 40 ml 
chloroprocaine 0.5 %  with 40 ml chloroprocaine 1 %  and found out 
that 1 % chloroprocaine results in an earlier onset of analgesia 
duration and improves distal tourniquet tolerance during IV regional 
anaesthesia. These beneficial effects must be weighed against a 
fourfold increase in signs of systemic local anaesthetic toxicity. 
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MATERIALS AND METHODS 
 This is a prospective double blind study conducted at 
Government Rajaji Hospital attached to Madurai Medical College. 
 After approval by the ethical committee 75 patients of ASA 
grade I & II  of ages between 15-70 years who came for upper limb 
surgeries which lasted for less than 60 minutes were included in this 
study. 
 Patients with history of allergy to local anaesthetics, sickle cell 
disease, Raynaud’s disease, scleroderma, local infection, Pagets 
disease and patients with inadequate starvation  <  6 hours and 
patients who had contraindication to Dexamethasone were excluded 
from this study.  Pre anaesthetic evaluation was done. 
 All patients were premedicated with Inj. Midazolam 2 mg  IM  
45 minutes before surgery.  Resuscitation equipment and drugs were 
kept ready.  Initial PR, BP, SPO2 were estimated continuously. 
 A 22 G cannula was placed intravenously as distal as possible 
in the arm to be anaesthetized.  Venous access is established in the 
opposite arm to allow administration of fluids or drugs if necessary.  
The double tourniquet was applied on the arm with generous layers 
of padding, ensuring that no wrinkles are formed and the tourniquet 
edges do not touch the skin.  The arm was exsanguinated by using 
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Esmarch bandage.  If this was impossible, exsanguination was 
achieved by elevating the arm for 2-3 minutes. 
 The proximal tourniquet was inflated to at least 100 mm Hg 
higher than the patients systolic blood pressure.  Before injecting 
local anaesthetic, radial pulse was palpated and confirmed that there 
was no pulse.  The local anaesthetic is then injected slowly over 90 
secs.  A standard volume of 40 ml of 0.5% lignocaine or 40 ml of 0.5 
mg lignocaine with dexamethasone was injected.  
              Patients were divided into three groups according to the drug 
which they received.  Group A- (CONTROL GROUP) patients 
received 40 ml of 0.5% lignocaine, group B patients(SUDY GROUP) 
received 40 ml of 0.5% lignocaine with 8 mg of Dexamethasone  and 
Group C(COMPARITIVE GROUP) patients received 40 ml of 
lignocaine with 8mg Dexamethasone intravenously in the opposite 
arm before the tourniquet was applied.  After achieving surgical 
anaesthesia, the distal tourniquet which overlies part of the 
anaesthetized arm was inflated and the proximal one was deflated.  
After that the surgeons were allowed to proceed. 
 Intraoperatively PR, BP, SPO2, signs of drug toxicity were 
monitored regularly. If  patient complained of tourniquet pain, they 
were supplemented with Inj. Midazolam IV (In titrated doses, max. 
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upto 2 mg) and  intercostobrachial N block with local infiltration 
around the cuff.  The cuff was not deflated until 20 minutes after 
local anaesthetic injection even if surgery was completed before 20 
minutes.  Cuff deflation was performed in cycles with deflation / 
inflation times of less than 10 seconds until the patient no longer 
exhibited signs of systemic toxicity.  Patients were observed for 30 
minutes after surgery. 
Intraoperatively the following parameters were noted : 
 1.Onset of  sensory and motor blockade. 
 2.PR, BP, SPO2 were monitored regularly at frequent 
intervals. 
 3.Duration of surgery  
 4.Need of supplementation for tourniquet pain 
 5.Side effects 
 6.Duration of blockade after cuff deflation both sensory & 
motor 
Post operatively the following parameters were noted : 
 1.Time for  first analgesic need.         
 
Statistical Tools  
 The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2002) 
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developed by Centers for Disease Control and Prevention (CDC), 
Atlanta for W.H.O. 
 
 Using this software, frequencies, percentage, range, mean, 
standard deviation, x2 and 'p' values were calculated. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
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RESULTS AND OBSERVATIONS 
A:  Profile of cases studied  
Table  1 :  Age distribution 
Group A 
Control group
Group B 
Study group 
Group C 
Comparative 
group 
Age 
Distribution 
No. % No. % No. % 
Upto  20 yrs 1 4 4 16 7 28 
21-30 11 44 10 40 8 32 
31-40 11 44 7 28 5 20 
>40 2 8 4 16 5 20 
Total 25 100 25 100 25 100 
Range 
Mean 
SD 
        18-45 yrs
30.9 
5.8 
        18-53 yrs 
30.7 
9.7 
        19-56 yrs 
30.1 
11.0 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.4517 Not Significant 
0.4086 Not Significant 
0.228 Not Significant 
0.6265 Not  Significant 
 
Comments:  
The difference between the groups with respect to age is not 
statistically significant. Hence the groups are comparable with 
respect to age. 
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Table 2  : Sex Distribution 
 
Group A 
Control group 
Group B 
Study group 
Group C 
Comparative 
group 
SEX 
No. % No. % No. % 
Male 16 64 12 48 17 68 
Female 9 36 13 52 8 32 
‘p’ value for 
A & B 
A & C 
B & C 
 
0.3927 Not Significant 
0.7676 Not Significant 
0.2517 Not Significant 
 
The difference between the groups with respect to sex is not 
statistically significant. Hence the groups are comparable with 
respect to sex. 
 
 
 
 
 
 
 
 
 52
 
 
 
Table 3 :  Weight  (in Kgs) 
 
Weight  
(in kgs) 
Group A 
Control group
Group B 
Study group 
Group C 
Comparative 
group 
Range 
Mean 
SD 
    42-60 yrs 
52.2 
5.1 
   40-59   yrs 
50.5 
6.0 
40-60  yrs 
49.8 
6.5 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.4517 Not Significant 
0.4086 Not Significant 
0.228 Not Significant 
0.6265 Not  Significant 
 
       The difference between the groups with respect to weight is 
not statistically significant. Hence the groups are comparable with 
respect to weight 
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B: Efficiency of the three groups 
Table 4:   Onset of sensory Block 
Onset of Sensory 
Block (in minutes) 
Group A(mins) 
Control group 
Group B(mins) 
Study group 
Group C(mins) 
Comparative group
Range 
Mean 
SD 
          2-9  
4.41 
1.55 
        2-7    
4.52 
1.36 
2-7  
4.82 
1.14 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.3269 Not Significant 
0.7406 Not Significant 
0.1479 Not Significant 
0.2918 Not  Significant 
 
  The onset of sensory blockade in Study Group was 4.52 
± 2.72 and control group was 4.41 ± 3.10 mins in the control group 
and 4.82 ± 2.28 mins in the Comparative groups respectively. 
Though the effects of dexamethasone appears to be superior, the 
effect was not statistically significant. The effects were almost same. 
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Table: 5  -  Onset of Motor Block (in minutes) 
 
Onset of Motor Block 
(in minutes) 
Group A 
(Control group) 
mins 
Group B 
(Study group) 
mins 
Group C 
(Comparative 
group)mins 
Range 
Mean 
SD 
       4-13  
7.18 
2.51 
4-11  
7.32 
1.68 
6-12  
7.74 
1.36 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.445 Not Significant 
0.5748 Not Significant 
0.1964 Not Significant 
0.5042 Not  Significant 
 
     The onset of motor blockade in study group was 7.32 ± 
3.36mins and control group was 7.18 ± 3.02 and 7.74 ± 2.72 
minutes respectively which was statistically not significant. 
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Table 6    :    Duration of Surgery (in minutes) 
Duration of Surgery  
(in minutes) 
Group A 
(Control group)
Group B 
(Study group) 
Group C 
(Comparative 
group) 
Range 
Mean 
SD 
 35-55  
46.0 
5.76 
30-56  
46.24 
6.16 
34-56  
44.04 
6.85 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.4754 Not Significant 
0.8374 Not Significant 
0.3208 Not Significant 
0.2752 Not  Significant 
 
 The duration of surgery in study groups were 46..24 ± 
12.32  and 46.04±11.52 mins in the control group and  it was 
44.04 minutes in the comparative groups respectively. The 
difference between the groups with respect to duration of surgery 
is not statistically significant. Hence the groups were comparable 
with respect to duration of surgery. 
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Table 7 : Duration of sensory block after cuff deflation  
(in minute) 
Duration of sensory block 
after cuff deflation (in 
minute) 
Group A 
Control group 
Group B 
Study group 
Group C 
Comparative 
group 
Range 
Mean 
SD 
3-7 
4.94 
1.53 
3-14  
7.8 
2.5 
2-10  
5.12 
2.11 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.0001  Significant 
0.0001  Significant 
  0.7757    Not Significant 
0.0003   Significant 
 
The duration of sensory blockade after cuff deflation in 
study groups were 7.8±5.0 mins and 4.94 ±3.06 mins in the 
control groups  and it was 5.12 ±4.24 mins in the comparative 
groups respectively.The duration of sensory blockade was longer  
in the study group and  it  was statistically significant, 
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Table 8   : Duration of motor block after cuff deflation 
Duration of Motor 
block after cuff 
deflation (in 
minutes) 
Group A 
(Control group) 
Group B 
(Study group)  
Group C 
(Comparative 
group) 
Range 
Mean 
SD 
    4-16  
7.56 
2.52 
5-20  
11.4 
3.39 
6-13  
          8.4 
         2.0 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
                              0.0001 Significant 
                              0.0001 Significant 
0.1008 Not Significant 
0.0006   Significant 
 
The duration of motor blockade after cuff deflation in 
study group was 11.4 ± 6.78  and  7.56 ± 5.04   in the control 
group and it was 8.4 ± 4.0 minutes in the comparative group  
respectively. The duration of blockade in the study group was 
found to be longer than that of control group and it was found to 
be statistically significant.  
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Table   9 : First Analgesic dose requirements 
First Analgesic 
dose 
requirements 
Group A 
Control group 
(mins) 
Group B 
Study group 
(mins)  
Group C 
Comparative 
group (mins) 
Range 
Mean 
SD 
12-24 
19.96 
9.26 
90-300  
167.12 
48.54 
18-40  
29.04 
6.12          
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.0001  Significant 
0.0001  Significant 
0.0001  Significant 
0.0001   Significant 
 
          The time for first analgesic requirements in study group 
was 167.12 ± 97.08 and 29.04± 12.24 mins in the comparative 
group and 19.96 ± 18.52 mins in the control groups respectively. 
The differences between the study group and the control group 
was statistically significant. The lowest duration achieved in the 
study group was 90minutes and longest duration was 300 
minutes. 
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Table 10 :  Tourniquet pain supplementation 
Group A 
(Control group) 
Group B 
(Study group) 
Group C 
(Comparative 
group) 
Tourniquet pain 
supplementation 
No. % No. % No. % 
Yes 15 60 5 20 13 52 
No 10 40 20 80 12 48 
‘p’ value for 
A & B  
A & C  
B & C 
 
0.0094  Significant 
      0.7757 Not Significant 
0.0392  Significant 
 
   In the study group 20% patients (5patients out of 25 
patients) needed supplementation due to tourniquet pain 
compared to 60%patients (15 patients out of 25patients) in the 
control group. The incidence of tourniquet pain in the study 
group was less and was statistically significant when compared 
to the control group. 
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Table 11: MAP changes after cuff deflation 
Group A 
Control group 
Group B 
Study group 
Group C 
Comparative group
 MAP changes 
after cuff deflation 
Mean SD Mean SD Mean SD 
1 Minute 
5  Minute 
Change in MAP 
% of Change 
89.14 
83.64 
8.46 
 9.51 
6.12 
8.76 
5.32 
5.9 
92.72 
85.36 
7.36 
7.78 
4.22 
3.6 
5.24 
5.32 
88.44 
85.0 
5.6 
6.18 
5.6 
3.25 
4.47 
4.77 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.1216  Not Significant 
0.4150  Not Significant 
0.0636  Not Significant 
0.214     Not  Significant 
 
The difference between the study and the control  groups with 
respect to mean arterial pressure at 1minute and at 5 mins  is not 
statistically significant. Hence the groups were comparable with 
respect to mean arterial pressure at 1 minute and 5 mins after 
cuff deflation. There were no side effects noted in both the 
groups after cuff deflation. 
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Table 12  :  Pulse Rate changes after cuff deflation 
Group A 
Control group 
Group B 
Study group 
Group C 
Comparative 
group 
Pulse Rate changes 
after cuff deflation 
Mean SD Mean SD Mean SD 
1 Minute 
5  Minute 
Change in MAP 
% of Change 
76.42 
73.96 
12.34 
15.89 
 
13.65 
4.82 
9.47 
12.06 
81.96 
83.64 
6.64 
8.28 
 
6.9 
4.23 
4.09 
5.52 
87.28 
78.84 
11.08 
12.5 
6.32 
5.55 
5.51 
5.92 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.118           Not Significant 
0.1113       Not Significant 
0.497        Not Significant 
0.2232      not  Significant 
 
The difference between the study and the control groups 
with respect to pulse rate which was recorded at 1 minute and  
5minutes after cuff deflation was not statistically significant. 
Hence both the groups were comparable and the differences 
were not statistically significant. There were no side effects 
noted after cuff deflation in both the groups. 
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DISCUSSION 
   Intravenous regional anaesthesia uses local anaesthetics 
administered to one particular limb by occluding the arm proximally 
to provide conduction blockade.  It must be safe, not threatening or 
unpleasant to the patient, allow adequate surgical access to the 
operative site, and cause as little disturbance as possible to the 
internal homeostatic mechanisms. 
Local anaesthetic diffuses into the small veins surrounding the 
nerves and then into the vasa nervorum and capillary plexus of the 
nerves, leading to a core to mantle (centrifugal) conduction block in 
the nerves involved. Local anaesthetic then diffuses into the small 
nerves in the skin, blocking their conduction. The tourniquet 
produces ischaemia, which contributes to the analgesic action of the 
local anaesthetic by blocking nerve conduction and motor endplate 
function. 20 minutes after tourniquet application alone there will be 
analgesia to pinprick without the injection of any local anaesthetic. 
However, the speed of onset and the density of anaesthesia are 
greater with injection of local anaesthetic. 
 Intravenous regional anaesthesia has many advantages. It is  
simple, reliable with rapid onset and recovery.  Despite these 
advantages intravenous regional anaesthesia has its own limitations 
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like lack of  postoperative analgesia and tourniquet pain which causes 
discomfort to the patient. In this study, we attempted to eliminate 
these disadvantages by adding  Dexamethasone as an adjuvant.   
Comparison of results: 
In this  study, the three groups that is the control group (Group 
A) -lignocaine only, study group (Group B)- lignocaine with 
Dexamethasone  and comparative group (Group C) lignocaine and 
intravenous-Dexamethasone in the opposite arm,in all these three 
groups  patients were comparable with  respect to  age, sex, weight 
and duration of surgery. 
Onset of sensory and motor blockade: 
The onset of sensory and motor blockade is similar in the three 
groups as compared to the original Zekiye Bigat study. 
Duration of sensory and motor block: 
The duration of sensory and motor block recovery times are 
much longer in the (study group )-Dexamethasone IVRA group when 
compared to the Dexamethasone intravenous group and the control 
group in my study.This is in contrast to the original study by Zekiye 
et al study. 
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Tourniquet Pain: 
The incidence of tourniquet pain was 20 % in Dexamethasone 
IVRA group 55 % in  Dexamethasone intravenous group and 60% in 
the control groups.This is a similar finding to the original study. 
Time to request of first analgesic: 
The time to request of first analgesic dose was mean time 
interval-167 mins in  the Dexamethasone IVRA group and in the 
comparative group and in the control groups it was 39 and 23 mins 
respectively.In the original study the time to request for the first 
analgesic was earlier in the IVRA Dexamethasone group but the total 
analgesic consumption for the first day was less in the IVRA 
Dexamethasone group.This result also correlates with the original 
study of Zekiye bagat et al.The p value was 0.001 which was 
clinically significant. 
 Surgical trauma results in release of intracellular contents from 
damaged and inflammatory cells.  Nociceptor stimulation causes a 
neurogenic response with release of mediators such as substance P 
and neurokinin A.  This results in an “inflammatory soup” containing 
histamine, serotonin, bradykinin and metabolites of the 
cyclooxygenase and lipooxygenase pathways.  
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          Dexamethasone depresses formation, release, and  activity of 
endogenous mediators of inflammation,including prostaglandins 
kinins, histamine, liposomal enzymes and complement expression. 
         The result is decreased afferent nociceptive signals arising from 
the site of surgery.  Whether interfering with the synthesis of 
inflammatory mediators has a preemptive analgesic role in preventing 
sensitization of nociceptors remains controversial. The role of 
Dexamethasone in the management of postoperative pain is well 
established.  Clinical studies have demonstrated an enhanced 
analgesic effect from Dexamethasone when concentrated at a 
peripheral site compared to the systemic administration of the same 
drug.  This would suggest a predominantly peripheral site of action.  .   
            It may be, that by concentrating the dose of Dexamethasone at 
the site of surgery, either as part of IVRA or wound infiltration, the 
resulting analgesic benefit is longer lasting than the same dose 
administered parenterally. Presumably there is a persistent drug level 
in the tissues, and this could result in reduced systemic side effects. 
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SUMMARY 
The aim of this study is to prove the effectiveness of 
Dexamethasone as an adjunct to IVRA.Its effectiveness in relieving 
tourniquet pain and post operative analgesia was also studied. 
        The study was conducted in Rajaji Hospital Madurai, both 
elective and emergency surgeries were included in this study. 
           The patients were  divided into three groups according to the 
drug which they received.  Group A (CONTROL GROUP) patients 
received 40 ml of 0.5% lignocaine, Group B patients(STUDY 
GROUP) received 40 ml of 0.5% lignocaine with 8 mg of 
Dexamethasone  and Group C(COMPARITIVE GROUP) patients 
received 40 ml of lignocaine with 8mg Dexamethasone intravenously 
in the opposite arm. 
 The parameters noted were : 
          1. Onset of  sensory and motor  blockade. 
2. PR, BP, SPO2 were monitored regularly at frequent 
intervals. 
 3. Duration of surgery  
 4. Need for supplementation in case of tourniquet pain. 
 5. Side effects 
 6. Duration of blockade after cuff deflation both sensory &  
  motor 
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Post operatively the following parameters were noted : 
 1. Time for first analgesic need. 
        After the entire study was conducted, it was found that adding 
Dexamethasone to lignocaine in IVRA yielded the following 
findings. 
1. Prolonged post operative analgesia 
2. Reduced tourniquet pain incidence. 
3. Better quality of analgesia intraoperatively. 
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CONCLUSION 
 Dexamethasone 8 mg which was added to Lignocaine for 
Intravenous regional anesthesia provides 
1. Less incidences of tourniquet pain 
2. Increases the duration of post operative analgesia 
3. No significant increase in side effects and there was no  
       haemodynamic changes. 
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PROFORMA 
Name   :     Age / Sex : 
IP No.  :     Weight : 
Diagnosis  :     ASA Risk : 
Surgery  : 
Premedication : 
1. Onset of action  : Sensory : 
    Motor : 
2. Side effects noted   : 
3. Duration of surgery  : 
Time Pre 5 10 15 20 30 40 60 75 90 120 
HR            
BP            
 
4. Supplementation : 
5. Duration of  blockade after cuff deflation : Sensory   : 
          Motor      : 
6. Post operative : 
  Time to first analgesic  : 
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1 marimuthu A M 22 48 F
T
I
I 4 6 45 3 5 15 yes 82 71.5 92 70
2 nagammal A F 28 50
Gang
II 4 7 50 3.5 4.5 13 yes 82.5 72 61 92
3 chinna maruthu A M 34 52
Gang
I 2 9 40 4 5 12 no 90 71.5 70 72
4 pandi A M 33 56
Gang
I 5 5 35 3.5 5.5 12 no 91 71 62 74
5 rakku A F 35 58
Gang
I 4 5 48 4 5.5 14 yes 80 76 59 75
6 lakshmi A F 37 52
R 
Radius II 4.3 5 50 4.5 6 13 yes 82 87 90 76
7 ponni A F 18 42
Gang
I 4 6 55 6 9 20 no 83 90 63.5 7
8 saroja A F 24 44
Gang
I 5 6 46 3 4 15 yes 83 96 64 72
9 kannan A M 29 54
Gang
I 6 13 39 7 9 14 no 83 90 62 70
10 gopal A M 41 59
Ext.Poi.
I II 7 9 43 6 9 20 yes 87 76 68 68
11 mageswari A F 45 45
Gang
I 9 11 47 7 9 23 no 88 84 70 70
12 kalaiyan A M 27 48
Gang
I 4 5 50 7 9 24 yes 98 85 94 72
13 thangaiah A M 34 60
RA  FA
I 5 6 42 4 8 14 no 91.5 89 80 74
14 muthuveeran A M 26 52
Gang
I 6 8 44 7 10 20 yes 90 78 83 76
15 perumalaiya A M 29 54
ETI
I 2 4 50 7 10 23 no 84 79 60 80
16 pothum ponnu A F 32 56
FTI
I 4 6 53 4 7 22 yes 100 102 74 70
17 azhagar A M 34 54
Gang
I 3 5 38 3.5 7 19 no 102.5 103.5 94 72
18 natarajan A M 33 58
LFA
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19 senthil A M 28 59
C F3-F5
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20 chinna ponnu A F 32 59
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21 thenappan A M 32 48
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I 3 4 38 7 10 15 yes 92 79 70 80
23 ayeesha beevi A F 25 50
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I 4 8 52 6 8 17 yes 92.5 81.5 92 74
25 abdul saleem A M 30 50
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28 pandiyammal B F 20 40
Gang
I 2 4 51 5 10 152 no 90 84 80 78
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32 kanimozhi B F 30 51
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33 jerina B F 32 54
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34 thayaleeswaran B M 27 58
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35 nagarajan B M 32 57
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36 rani B F 30 50
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